{"id":"placebo-to-match-saxagliptin","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2103745","moleculeType":"Small molecule","molecularWeight":"333.43"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo to match saxagliptin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:46:30.505742+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:46:35.848688+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo to match saxagliptin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:46:36.245923+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2103745/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:46:36.995863+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos contain no active pharmaceutical ingredient and produce no pharmacological effect. They are used in randomized controlled trials to provide a control arm that is indistinguishable from the active drug in appearance, taste, and administration route, allowing for assessment of the true efficacy of the active comparator (saxagliptin) by controlling for placebo effect.","oneSentence":"This is an inert placebo formulation designed to match the appearance and administration of saxagliptin for blinded clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:42:07.951Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:46:38.598199+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Control arm in clinical trials of saxagliptin (DPP-4 inhibitor for type 2 diabetes)"}]},"trialDetails":[{"nctId":"NCT03199053","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":"Diabetes Mellitus, Type 2","enrollment":256},{"nctId":"NCT03608358","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-02-27","conditions":"Type 2 Diabetes Mellitus","enrollment":41},{"nctId":"NCT02917031","phase":"PHASE4","title":"Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-01-10","conditions":"Type 2 Diabetes Mellitus, Heart Failure","enrollment":348},{"nctId":"NCT02547935","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-21","conditions":"Type 2 Diabetes Mellitus, CKD and Albuminuria","enrollment":459},{"nctId":"NCT02284893","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-09","conditions":"Type 2 Diabetes","enrollment":461},{"nctId":"NCT01606007","phase":"PHASE3","title":"Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-07","conditions":"Type 2 Diabetes","enrollment":1282},{"nctId":"NCT01204775","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-06","conditions":"Type 2 Diabetes","enrollment":26},{"nctId":"NCT01434186","phase":"PHASE3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT01646320","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT01619059","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Type 2 Diabetes","enrollment":315},{"nctId":"NCT00918138","phase":"PHASE3","title":"Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Type 2 Diabetes","enrollment":219},{"nctId":"NCT00121641","phase":"PHASE3","title":"Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-07","conditions":"Diabetes Mellitus, Type 2","enrollment":1035},{"nctId":"NCT00614939","phase":"PHASE3","title":"Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-01","conditions":"Type 2 Diabetes","enrollment":572}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL2103745"},"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo to match saxagliptin","genericName":"Placebo to match saxagliptin","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is an inert placebo formulation designed to match the appearance and administration of saxagliptin for blinded clinical trials. Used for Control arm in clinical trials of saxagliptin (DPP-4 inhibitor for type 2 diabetes).","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T06:46:38.598199+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}